Graminol

Quick links to important sections

Graminol

Method of action: Antiemetic

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Graminol

This section provides a factual definition of Graminol, detailing its identity, composition, and general classification.

Property Description
Active Ingredient Dimenhydrinate
Form Oral preparations (e.g., tablets)
Pharmacological Class Anti-emetic; Antihistamine H1-receptor antagonist
Common Use Prevention and relief of motion sickness
Origin Synthetic compound

What is Graminol and How is it Classified?

Graminol is the trade name for a medication whose active substance is Dimenhydrinate, a compound clinically recognized as an effective anti-emetic agent used to manage symptoms like nausea, vomiting, and dizziness. Dimenhydrinate is also categorized specifically as a first-generation antihistamine H1-receptor antagonist. This medicine is a synthetic compound typically presented for oral preparation, such as a tablet.

Chemically, the active ingredient is a single molecule that is a salt, combining the antihistamine Diphenhydramine with the milder stimulant 8-chlorotheophylline in a fixed ratio, a structure necessary for its intended therapeutic effects. This specific fixed-combination structure is the differentiating characteristic of the Dimenhydrinate entity itself, ensuring a targeted action against motion sickness symptoms rather than solely allergy relief.

Composition, Forms, and General Therapeutic Purpose

The core composition of this medicine relies exclusively on Dimenhydrinate as the active ingredient. The medication’s general therapeutic purpose is to prevent and relieve symptoms associated with motion and disturbances of the inner ear, known as the labyrinth. It is widely utilized as a means of managing the uncomfortable physical effects of motion sickness (kinestosis) and other forms of vertigo. Evaluations confirm that the medication is effective in stabilizing symptoms resulting from balance system overstimulation. The functional benefit, therefore, derives from the drug's ability to minimize feelings of nausea, suppress the urge to vomit, and alleviate accompanying sensations of dizziness and sickness.

Regulatory References

  1. Dimenhydrinate: MedlinePlus Drug Information
  2. Dimenhydrinate - LiverTox
  3. Public Assessment Report (CBG-MEB)

What side effects are possible with Graminol?

Possible Side Effects and Safety Information

The safety profile of Graminol (Dimenhydrinate) is primarily characterized by effects related to its action on the central nervous system (CNS) and its anticholinergic properties, as documented in official regulatory sources. Drowsiness is classified as the most frequent adverse reaction.


Adverse Reactions by System-Organ Class

The officially documented adverse effects involve several system-organ classes, including:

  • Nervous System Disorders: Drowsiness, dizziness, headache, and potential for paradoxical excitation.
  • Gastrointestinal Disorders: Dry mouth, dry throat, anorexia (loss of appetite), and stomach upset (epigastric distress).
  • Ocular Disorders: Blurred vision.
  • Cardiac Disorders: Tachycardia (fast heartbeat) and palpitations.

Safety Considerations and Restrictions

Official labeling includes specific restrictions due to the potential for impaired coordination. The medicine may impair the ability to perform potentially hazardous tasks such as operating machinery or driving a vehicle. The risk of additive CNS effects is noted when used concomitantly with alcohol or other sedatives.

Caution is advised in individuals with certain pre-existing conditions that may be aggravated by anticholinergic therapy, such as narrow-angle glaucoma or prostatic hypertrophy (difficulty urinating), consistent with official regulatory guidelines.

Population-Specific Notes

The regulatory documents highlight that pediatric patients may experience excitation or restlessness rather than the expected sedation. Furthermore, older adults may exhibit increased sensitivity to the anticholinergic and sedative effects. Use during pregnancy and lactation should be assessed by a health professional and is advised only if clearly needed.


Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation defines Graminol (Dimenhydrinate) overdosage by a range of documented clinical manifestations, requiring specific emergency responses. Overdose presentations are characterized by signs of both Central Nervous System (CNS) stimulation (e.g., agitation, delirium, hallucinations, tremor) and subsequent CNS depression leading to coma. Anticholinergic signs, such as dry mouth and dilated pupils, are also documented.


Life-Threatening Manifestations

Severe outcomes officially listed include neurological events like seizures and convulsions, along with potentially fatal cardiac arrhythmias (including QRS widening and QTc prolongation), respiratory depression, and cardiac arrest. Pediatric patients are specifically noted in regulatory labels as being at higher risk for CNS stimulation, convulsions, and death from overdosage.


Immediate Actions

The official label mandates that immediate medical attention must be sought in all cases of suspected overdose. Management is generally described as symptomatic and supportive treatment. Procedural steps documented include close cardiac monitoring (ECG) and the use of measures such as activated charcoal and gastric lavage in appropriate settings. For specific symptoms, benzodiazepines may be used to manage seizures or agitation, while CNS stimulants are explicitly contraindicated.

Therapeutic Uses of Graminol

Quick Facts

  • Primary Use: Management of specific bacterial infections.
  • Function: Offers therapeutic support for infectious disease states.
  • Benefit Profile: Intended to help address signs and symptoms of associated conditions.

Graminol is a therapeutic agent that serves in the management of infectious disease states caused by susceptible organisms. It is indicated for use across a spectrum of specific bacterial conditions, including certain rickettsial infections, as well as those related to Streptococcus and Staphylococcus species. It may be used to provide therapeutic support for patients experiencing conditions like Rocky Mountain spotted fever, pertussis, and infections caused by Hemophilus influenzae.

Its intended benefit is to help reduce the presence of the infectious agent, thereby contributing to the resolution or improvement of associated symptoms and the underlying condition. The medication is utilized as a part of a supervised treatment plan to address the disease process.

Patients considering Graminol should discuss their overall health status and treatment goals with a qualified healthcare professional. It is available to help manage the specified conditions when deemed appropriate by a doctor.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Graminol

The eligibility for Graminol (Dimenhydrinate) is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Absolute Contraindications (Must Not Use)

Graminol is contraindicated and must not be used by specific patient populations, including:

  • Patients with a known hypersensitivity to dimenhydrinate, its components (Diphenhydramine, 8-chlorotheophylline), or any ingredient in the formulation.
  • Neonates and Premature Infants (especially for injectable formulations).
  • Individuals currently taking or who have recently taken (within 14 days) a Monoamine Oxidase Inhibitor (MAOI).

Age-Based Eligibility

The medicine is generally indicated for Adults and Adolescents (age 12 years and older) and Children (age 2 to 11 years). However, restrictions apply to the following groups:

  • Children under 2 years of age are generally not recommended to use the oral formulation unless under the strict direction of a healthcare professional.
  • Older Adults (age 65 years and older) are subject to caution, as regulatory criteria identify this medication as potentially inappropriate due to heightened risk of adverse effects.

Condition-Specific Restrictions

Conditional use is required, or specific restrictions apply, for patients with the following existing conditions:

  • Glaucoma (Narrow-Angle).
  • Chronic Lung Disease (e.g., Emphysema, Chronic Bronchitis).
  • Conditions causing difficulty urinating, such as Prostatic Hypertrophy or bladder-neck obstruction.
  • Seizure disorders or Cardiovascular Disease.

Pregnancy and Lactation Status

  • Pregnancy: The medication is generally classified as Pregnancy Category B by the US FDA; however, use during pregnancy is advised only if clearly needed.
  • Lactation: Small amounts are excreted into breast milk. Regulatory guidance requires a decision to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Graminol's official interaction profile is characterized by pharmacodynamic additive effects and specific regulatory constraints. Co-administration with alcohol or other Central Nervous System (CNS) Depressants (including sedatives, opioids, and tranquilizers) results in an additive sedative effect, significantly increasing the risk of drowsiness and impaired function. Similarly, concurrent use with Anticholinergic Drugs, such as tricyclic antidepressants, may potentiate the overall anticholinergic effects.

Formal regulatory prohibitions define key restrictions. The medication is contraindicated for co-administration with other products containing Diphenhydramine and specific Class I and Class III Antiarrhythmics, due to the risk of cardiac arrhythmias. Regulatory labeling also specifies that Monoamine Oxidase Inhibitors (MAOIs) should be avoided concurrently or for 14 days following their cessation.

A documented pharmacokinetic interaction involves the CYP2D6 hepatic enzyme, which Graminol inhibits. This mechanism can lead to increased exposure of co-administered CYP2D6 substrate medications (e.g., Metoprolol, Venlafaxine). Furthermore, Graminol may mask the symptomatic early warnings of ototoxicity caused by other medications, such as certain antibiotics. Administration is contraindicated in Neonates and Premature Infants, and the Elderly population is noted to be more susceptible to enhanced additive side effects.

Mechanism of Action

Central Inhibition of Motion and Balance Signals

Graminol's primary mechanism involves central nervous system activity. Its active moiety, Diphenhydramine, acts as a competitive antagonist at both the Histamine H1 and Muscarinic Acetylcholine receptors within the brainstem, particularly in the vestibular nuclei and the Vomiting Center. This dual receptor blockade functionally depresses the transmission of excessive neural signals originating from the inner ear's balance mechanisms, a key physiological process in modulating activity within the vestibulo-autonomic pathways.


Functional Balancing of Pharmacological Effects

The medication is a fixed salt that also includes 8-chlorotheophylline, which provides a distinct secondary mechanistic domain. This component acts as an antagonist of adenosine receptors, engaging a mechanism that influences the central nervous system arousal state. This secondary action modulates the functional profile of the drug by modifying the central depressant effect that can result from the H1 antagonism, contributing to the overall physiological profile associated with the mechanism.

Dosage and Administration Information

Graminol (Dimenhydrinate) is available for administration via multiple routes, including oral (tablets and liquid solutions), intramuscular (IM), intravenous (IV), and rectal (suppository) forms, which offers flexibility based on clinical need. Parenteral forms are generally reserved for situations where the oral route is not practical or feasible.

The standard dose for adults and individuals 12 years and older for oral use is 50 mg to 100 mg per dose. This is administered every 4 to 6 hours as needed. The total dose is not to exceed 400 mg in a 24-hour period. When Graminol is used for preventative purposes, the first dose is scheduled to be taken 1/2 to 1 hour before the start of the activity, and intake is permitted either with or without food.

Dosing for pediatric patients is defined by age group and maximum daily limits. For instance, children aged 6 to 11 years are administered 25 mg to 50 mg every 6 to 8 hours, with a maximum daily limit of 150 mg. Specialized procedural requirements exist for injectable use: the IV solution must be diluted in 10 mL of 0.9% Sodium Chloride Injection and must be administered slowly over a period of 2 minutes. This structure defines the high-level, intermittent use protocol for the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Graminol


Evidence for Motion Sickness: Prevention and Acute Treatment

Graminol (Dimenhydrinate) was studied in research exploring symptom patterns related to motion sickness through a body of short-term Randomized Controlled Trials (RCTs). These research examined how patient-reported outcomes describing perceived discomfort were measured during use of the study drug compared to a placebo. The outcomes measured included the frequency of vomiting and the severity of nausea, often assessed using patient-reported scales. These trials were typically relevant in trials assessing short-term or episodic symptom patterns, focusing on the duration of a single trip or motion exposure. Long-term effects are not fully established because the most robust trials follow-up durations were limited to the short, acute period of motion exposure.


Research on Vertigo and Dizziness Relief

Research examined studies conducted for the symptoms of vertigo and dizziness, which are conditions characterized by fluctuating or episodic manifestations often linked to inner ear disturbances. These studies, including RCTs, have used in research exploring how symptoms change over time, measuring patient-reported outcomes describing perceived discomfort such as the intensity of spinning and unsteadiness. Research explored studies evaluating the compound both as a single agent and as part of a fixed-combination product. The body of evidence is limited for Graminol's evaluation as a monotherapy (by itself) specifically for chronic, non-motion-related vertigo. Follow-up durations were limited in these studies, focusing mainly on immediate symptom relief rather than sustained management.


Studies on General Nausea and Vomiting (Non-Motion Related)

Research examined studies conducted during periods of increased symptom activity related to non-motion nausea and vomiting. Studies monitored outcomes in two primary settings: the prophylaxis of post-operative nausea and vomiting (PONV) in surgical patients, and the management of vomiting due to acute gastroenteritis in children. The patient-reported outcomes describing perceived discomfort measured the number of vomiting episodes over a defined short-term period (e.g., 6 to 48 hours). Data for certain groups remain insufficient outside of the post-operative and acute gastroenteritis scenarios, and the results apply only to the populations studied.


Understanding Research Gaps and Uncertainties

Despite the historical and consistent research in acute motion sickness, several research limitation frames define the current evidence landscape. Comparative evidence is lacking in modern trials that assess Graminol against all newer pharmacological agents available today. Furthermore, there is limited information for long-term outcomes or the safety profile associated with continuous, chronic use of the study drug. Evidence highlights what is known — and what is still uncertain, confirming that while acute-use research is available, data are still emerging for broader application scenarios.

Key Studies & References

  1. Label: Dramamine original formula- dimenhydrinate tablet (FDA/DailyMed Product Information)
  2. Arlevert 20mg/40mg Tablets Public Assessment Report (European Regulatory Document concerning the fixed combination)

Frequently Asked Questions (FAQ)

Common questions about Graminol (FAQ)

Q: Are there certain foods or drinks I should avoid while using Graminol?

Regulatory documents state that Graminol can be taken with or without food. However, the official product information strongly warns against co-administering this medicine with alcohol. This is because alcohol can lead to additive sedative effects, significantly increasing the risk of drowsiness and impaired function.

Q: Does Graminol cause any long-term health concerns?

Official documentation indicates that studies focused primarily on short-term and intermittent use of the medicine. Because of this, evidence is limited regarding the safety profile associated with continuous, chronic use. The medication is generally intended for as-needed symptom management.

Q: Can Graminol be taken with blood pressure medication?

Official information indicates that Graminol can inhibit a liver enzyme known as CYP2D6. This mechanism can lead to increased exposure of other medications that are broken down by this enzyme, including some blood pressure medications. Patients are advised to share their full list of medications with their healthcare provider to screen for potential interactions.

Q: What is the difference between Graminol and its generic version?

Graminol is the trade name for the active substance dimenhydrinate. Official product information defines this substance as a fixed salt, which is a combination of two specific components. The generic version contains this same active substance.

Q: Is there a maximum time someone can stay on Graminol?

According to the official product information, this medication is intended for short-term, intermittent use, administered only as needed for symptoms. Official regulatory documents do not provide established long-term dosing protocols or a defined maximum duration for continuous, chronic use.

Q: Does the time of day matter when taking Graminol?

The official timing of Graminol is primarily relevant to the activity for which symptom prevention is desired. For preventative purposes, the first dose is administered 1/2 to 1 hour before the activity begins. Subsequent doses are then administered intermittently as needed.

Q: Does Graminol interact with common cold or flu remedies?

The official interaction profile notes that Graminol has additive sedative effects when combined with Central Nervous System (CNS) depressants. Many common cold and flu remedies contain ingredients like diphenhydramine or other depressants, which is a factor to be aware of if concurrent use is being considered.

Q: How quickly does Graminol start to work after I begin taking it?

Official administration guidance indicates a timing of 1/2 to 1 hour before the start of a motion-inducing activity for preventative purposes. This timing reflects the amount of time needed for the medicine to become available in the system for its intended effect.

Q: What happens if I forget to take a dose of Graminol?

Graminol is typically prescribed for as-needed use, rather than a scheduled daily regimen. If a dose was planned for prevention or symptom relief, official guidance suggests following the directions provided by a healthcare professional.

Q: Is Graminol physically addictive or habit-forming?

Regulatory documentation does not list physical dependency or abuse potential in its official warnings. Furthermore, this medicine is not classified as a controlled substance by governmental regulatory bodies.

Q: Is Graminol a controlled substance?

According to regulatory documents, Graminol is not classified as a controlled substance. Controlled substances are drugs that are subject to stricter governmental controls due to their potential for abuse or dependency.

Q: If I feel better, is it okay to stop taking Graminol?

Official guidance states that this medication is intended for intermittent, as-needed use to manage short-term symptoms like motion sickness. Since it is not typically prescribed as a continuous course, the need for the medicine is generally based on the presence of symptoms.

Q: Does Graminol interact with common over-the-counter pain relievers?

The official interaction profile cautions against the additive effects of Central Nervous System (CNS) depressants. While many common over-the-counter pain relievers are safe to use, some may contain ingredients that cause drowsiness or are classified as CNS depressants, which requires careful attention.

Q: I heard Graminol can cause a rash; how serious is that side effect?

Official documentation lists the most common side effects, but hypersensitivity reactions are noted as a contraindication for use. Hypersensitivity may sometimes include dermatological responses, and any sign of a severe reaction may warrant contacting a healthcare professional.

Q: What if I experience a rare or unusual side effect while on Graminol?

Regulatory bodies advise that patients experiencing any unexpected, serious, or rare adverse events can be reported promptly. This reporting can be directed to a healthcare professional or directly to the national drug monitoring system, such as the FDA MedWatch program.

Q: Does Graminol affect lab test results?

Official regulatory documents indicate that the active ingredient may interfere with certain skin tests that use allergens. This interference can sometimes lead to results that appear falsely negative.

Q: What happens if I take more Graminol than prescribed?

Official labeling addresses the risk of taking more than the prescribed amount. Symptoms of overdose are described as potentially exaggerated versions of the known adverse reactions or severe central nervous system effects.

Q: Where can I find the official patient information leaflet for Graminol?

Patient Information Leaflets (PIL) and Medication Guides are officially published resources that contain the full product information. These documents are generally available for search and download on the websites of national regulatory authorities, such as the FDA (DailyMed) or your local government drug agency.

How should Graminol be stored and disposed of?

How to Store and Dispose of Graminol

Graminol must be stored under specific conditions to maintain its stability and effectiveness, as defined by regulatory documents.

Storage Requirements

The medication requires storage at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be stored in its original container and kept tightly closed to protect it from moisture. It is mandatory to keep Graminol out of the sight and reach of children and pets. The medicine must not be frozen and should not be used past the expiration date printed on the packaging.

Disposal Instructions

To dispose of unused or expired Graminol, follow the instructions provided by local regulations or a drug take-back program. It is generally advised not to flush the medication down a toilet or pour it down a drain unless the official labeling specifically instructs this method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Graminol found in:

A-Z Index: